Results 31 to 40 of about 19,293 (297)

Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?

Cancer Treatment and Research Communications, 2022
Introduction: The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated.
Valentina Ghirardi, Francesca De Felice, Marco D'Indinosante, Federica Bernardini, Maria Teresa Giudice, Anna Fagotti, Giovanni Scambia   +6 more
doaj   +1 more source

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)

Journal of Gynecologic Oncology, 2022
Objective To investigate the health-related quality of life (HRQOL) related to hyperthermic intraperitoneal chemotherapy (HIPEC) following primary or interval cytoreductive surgery for primary ovarian cancer. Methods Between 2010 and 2016, a total of 184
J. Kim, Dong-eun Lee, Yumi Lee, H. I. Ha, Y. Chang, Suk-Joon Chang, Sang-Yoon Park, M. Lim   +7 more
semanticscholar   +1 more source

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

Molecules, 2020
Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity ...
Galina Kireeva, Stepan Kruglov, Mikhail Maydin, Ekaterina Gubareva, Elena Fedoros, Ekaterina Zubakina, Natalya Ivanenko, Marina Bezruchko, Nikolay Solovyev   +8 more
doaj   +1 more source

The efficacy of traditional chinese medicine combined with hyperthermic intraperitoneal chemotherapy for malignant ascites: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Objective: Malignant ascites (MA) is a common complication of terminal cancer, which seriously affects the life quality and prognosis of patients. Both hyperthermic intraperitoneal chemotherapy (HIPEC) and traditional Chinese medicine (TCM) preparations ...
Zhixian Lin, Jiangfeng Chen, Yunxia Liu
doaj   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]

, 2017
Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele, Christopoulou, Athina, Ciardi, Antonio, Cornali, Tommaso, Efstathiou, Elias, Framarino dei Malatesta, Marialuisa, Kopanakis, Nikolaos, Sammartino, Paolo, Spagnoli, Alessandra, Spiliotis, John   +9 more
core   +1 more source

HIPEC in Peritoneal Metastasis of Gastric Origin: A Systematic Review of Regimens and Techniques

Journal of Clinical Medicine, 2022
(1) Background: Peritoneal metastasis in gastric cancer is associated with a poor prognosis. Complete cytoreductive surgery including gastrectomy and complete removal of all peritoneal lesions followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Felix Gronau, Linda Feldbruegge, Frauke Oberwittler, S. González-Moreno, L. Villeneuve, C. Eveno, O. Glehen, S. Kusamura, B. Rau   +8 more
semanticscholar   +1 more source

Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers

International Journal of Molecular Sciences, 2022
Most patients with epithelial ovarian cancers (EOCs) are at advanced stages (stage III–IV), for which the recurrence rate is high and the 5-year survival rate is low.
Pei-Qi Lim, I. Han, K. Seow, Kuo-Hu Chen
semanticscholar   +1 more source

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio, Biacchi, Daniele, Cardi, Maurizio, DI GIORGIO, Angelo, Mingarelli, Valentina, Musio, Daniela, Sammartino, Paolo, Sibio, Simone, Sollazzo, BIANCA MARIA   +8 more
core   +2 more sources

Limitations of laparoscopy to assess the peritoneal cancer index and eligibility for cytoreductive surgery with HIPEC in peritoneal metastasis

Langenbeck's archives of surgery (Print), 2022
We aimed to determine the value of laparoscopy to assess the intra-abdominal tumor extent and predict complete cytoreduction. All patients at our department in the period from 2017 to 2021 that underwent laparoscopy to assess peritoneal metastasis and ...
C. Yurttas, L. Überrück, Giorgi Nadiradze, A. Königsrainer, P. Horvath   +4 more
semanticscholar   +1 more source

Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]

, 2019
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica, Cardi, Maurizio, D'Agostino, Claudia, Fonsi, Giovanni Battista, Francesco Di Marzo,, Francesco, Lefoche, LA TORRE, Giuseppe, Sammartino, Paolo, Sibio, Simone   +8 more
core   +1 more source